" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OriGene Awarded NCI Contract

Published: Monday, February 03, 2014
Last Updated: Monday, February 03, 2014
Bookmark and Share
The contract will see OriGene to develop high affinity anti-peptide antibodies for SISCAPA assays.

Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) , an approach developed by Dr. Leigh Anderson , is a novel technology that  can achieve high sensitivity quantitation of proteins in clinical samples using  affinity - capture  SRM Mass spectrometry. One of the most desirable aspects of SISCAPA technology is that it h as the potential for simultaneous quantification of multiple  proteins from a given sample making it is highly desirable in  many applications to minimize sample requirements, handling, and assay costs per analyte . However, the capabilities of the SISCAPA technique are currently limited due to the scarcity of high  affinity antibodies to the specific peptides that are generated by the fragmentation  of the target  protein before analysis.  

Producing high quality antibodies for SISCAPA assays fits well with OriGene's long term goal  of developing perfect assays for every human protein. The development of these  antibodies is being performed  in  partnership with the Institute for Systems Biology (ISB) and in  coordination with NCI's Clinical Proteomic Technologies for Cancer (CPTC) group. OriGene has previously collaborated with Dr. Robert Moritz , Director of Proteomics Research at ISB , for the generation  of mass spec peptide profiles from over 5000  full length  human proteins for inclusion in the complete human SRMAtlas . For the generation of high - affinity SISCAPA antibodies under this contract, OriGene will utilize a novel immunization  strategy to develop high antibody titers in rabbits and will utilize the  proteomics capabilities of the Moritz lab to identify , isolate and characterize the highest affinity antibodies suitable for SISCAP A approaches . 

Dr. James Lazar, Vice President of Assay Development said, “OriGene is pleased to have been selected by NCI to receive this contract and to work with Dr. Moritz , a leader in this field. We believe that OriGene’s unique expertise in antibody development  will enable the true potential of SISCAP A technology and contribute to the development of important clinical assays”. 

Dr. Moritz commented : “ This is a fantastic opportunity  where we continue our collaboration  with OriGene  and combin e our collective knowledge and expertise in antibody generation and  protein chemistry to provide  ‘digitized ’ antibodies for the NCI CPTC program at the NIH and  support the effort of shared resources .”  


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OriGene Awarded Contract to Develop Monoclonal Antibodies for SISCAPA
OriGene Technologies have announced that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.
Monday, January 11, 2016
OriGene Technologies Announces the Acquisition of ZsBio
Acquisition establishes OriGene's leading position in the Chinese pathology testing market.
Tuesday, March 13, 2012
OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
Extensively validated monoclonal antibodies made against native protein antigens for superior IHC, IF, ELISA and flow applications.
Monday, January 24, 2011
OriGene Technologies Acquires Blue Heron Biotechnology
OriGene’s collection of human cDNA clones together with Blue Heron’s gene synthesis capacity provides a whole product solution for the life sciences community.
Tuesday, August 17, 2010
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!